Director Meghan Fitzgerald filed a Form 4 with the SEC on September 18, 2026, disclosing the receipt of annual restricted stock unit and stock option awards in Roivant Sciences Ltd. (NASDAQ:ROIV) on September 16, 2026.

Key Highlights

  • RSU Grant: Fitzgerald received 5,054 restricted stock units at a price of $0, representing an annual director award under the company's 2021 Equity Incentive Plan.
  • Stock Option Grant: Fitzgerald also received 10,531 stock options to purchase Common Shares at an exercise price of $39.57, expiring September 15, 2036.
  • Vesting Schedule: Both the RSUs and stock options are scheduled to vest 100% on September 16, 2027, subject generally to continued service as a director.
  • Post-Transaction Ownership: Following the reported transactions, Fitzgerald directly holds 41,162 Common Shares and 10,531 derivative securities.
  • Policy Basis: Both awards were granted pursuant to the company's 2021 Equity Incentive Plan and its Non-Employee Director Compensation Policy.

Meghan Fitzgerald's Annual Director Equity Awards at Roivant Sciences

According to the filing, Meghan Fitzgerald, a director of Roivant Sciences Ltd. (NASDAQ:ROIV), received two equity awards on September 16, 2026. The first was a grant of 5,054 restricted stock units tied to Common Shares, acquired at a price of $0. The filing states this reflects "an annual award of restricted stock units" granted under the company's 2021 Equity Incentive Plan and its Non-Employee Director Compensation Policy.

The second award consisted of 10,531 stock options to purchase Common Shares, with a conversion or exercise price of $39.57 per share and an expiration date of September 15, 2036, also acquired at a price of $0. The filing describes this as "an annual award of stock options to purchase Common Shares" under the same plan and policy. Both awards are scheduled to vest 100% on September 16, 2027, "subject generally to the reporting person's service as a director through such date," as the filing states.

Following these transactions, the filing reports Fitzgerald directly holds 41,162 Common Shares and directly owns 10,531 derivative securities in the form of stock options. The Form 4 was signed by Sam Kaplan as attorney-in-fact for Meghan Fitzgerald and filed on September 18, 2026.

What Was Disclosed

Roivant Sciences director Meghan Fitzgerald disclosed receiving 5,054 RSUs and 10,531 stock options on September 16, 2026, both granted as annual director awards under the company's 2021 Equity Incentive Plan, with vesting scheduled for September 16, 2027.